Zynex (ZYXI) Expected to Announce Earnings on Tuesday

Zynex (NASDAQ:ZYXI) is projected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Zynex to post earnings of $0.09 per share and revenue of $53.65 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Zynex Stock Up 1.1 %

Shares of NASDAQ:ZYXI opened at $7.35 on Monday. The stock has a market cap of $234.07 million, a price-to-earnings ratio of 49.00 and a beta of 0.81. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex has a 12-month low of $7.00 and a 12-month high of $13.19. The business’s 50 day moving average is $7.75 and its 200 day moving average is $8.03.

Insiders Place Their Bets

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the transaction, the chief financial officer now owns 19,738 shares of the company’s stock, valued at approximately $151,587.84. The trade was a 33.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 30,000 shares of company stock valued at $227,100. Insiders own 52.13% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Zynex in a research report on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.